|Home | About | Journals | Submit | Contact Us | Français|
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
15-Lipoxygenase 2 (15-LOX2), a lipid-peroxidizing enzyme, is mainly expressed in the luminal compartment of the normal human prostate and often decreased or lost in prostate cancer. Previous studies from our lab implicate 15-LOX2 as a functional tumor suppressor. To better understand the biological role of 15-LOX2 in vivo, we established prostate-specific 15-LOX2 transgenic mice using the ARR2PB promoter. Unexpectedly, transgenic expression of 15-LOX2 or 15-LOX2sv-b, a splice variant that lacks the arachidonic acid metabolizing activity, resulted in age-dependent prostatic hyperplasia and enlargement of the prostate. Prostatic hyperplasia induced by both 15-LOX2 and 15-LOX2sv-b was associated with an increase in luminal and Ki-67+ cells; however, 15-LOX2-transgenic prostates also showed a prominent increase in basal cells. Microarray analysis revealed distinct gene expression profiles that could help explain the prostate phenotypes. Strikingly, 15-LOX2, but not 15-LOX2sv-b, transgenic prostate showed upregulation of several well-known stem/progenitor cell molecules including Sca-1, Trop2, p63, Nkx3.1 and Psca. Prostatic hyperplasia caused by both 15-LOX2 and 15-LOX2sv-b did not progress to prostatic intraprostate neoplasia (PIN) or carcinoma and, mechanistically, prostate lobes (especially those of the 15-LOX2 mice) showed a dramatic increase in senescent cells as revealed by increased SA-βgal, p27Kip1 and HP1γ staining. Collectively, our results suggest that 15-LOX2 expression in mouse prostate leads to hyperplasia and also induces cell senescence, which may, in turn, function as a barrier to tumor development.
15-Lipoxygenase-2 (15-LOX2) is a human-specific, non-heme, and iron-containing enzyme that preferentially metabolizes arachidonic acid (AA) to 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE] (Brash et al., 1997). 15-LOX2 has only ~40% sequence homology to human 15-LOX-1 and 12-LOX but displays 78% sequence homology to the murine ortholog, 8-LOX (Jisaka et al., 2000). 15-LOX2 shows a limited tissue distribution and is primarily expressed in the prostate, lung, skin, cornea and esophagus (Brash et al., 1997). Different from 15-LOX2, 8-LOX is not expressed in the murine prostate (Jisaka et al., 1997; Kim et al., 2005; Shappell et al., 2003). The preferential expression of 15-LOX2 in differentiated cells suggests that it may be involved in cellular differentiation and/or secretory functions, although its physiological cellular functions remain poorly characterized.
Strong clinical and experimental evidence has implicated 15-LOX2 as a functional tumor suppressor. FIRST, 15-LOX2 expression and enzymatic activity are frequently downregulated or lost in high-grade prostate intraepithelial neoplasia (HGPIN) and prostate cancer (PCa) (Jack et al., 2000; Shappell et al., 1999) as well as in the cancers of the skin (Shappell et al., 2001), lung (Gonzalez et al., 2004), breast (Jiang et al., 2006), head and neck (Wang et al., 2006), and esophagus (Xu et al., 2003). SECOND, restoration of 15-LOX2 expression in PCa cells inhibits cell proliferation in vitro and tumor development in vivo (Bhatia et al., 2003; Tang et al., 2002; Tang et al., 2009). THIRD, exogenous 15(S)- HETE, the main 15-LOX2 metabolite, inhibits proliferation or induces apoptosis in PCa (Tang et al., 2002), colon cancer (Chen et al., 2003) and CML (Mahipal et al., 2007) cells. FOURTH, 15-LOX2 functions as a negative cell-cycle regulator in normal human prostate (NHP) epithelial cells (Tang et al., 2002). Moreover, it is cell-autonomously induced prior to NHP cell senescence and its ectopic expression in NHP and PCa cells promotes senescence (Bhatia et al., 2005). Of significance, similar to these tumor-suppressive functions of human 15-LOX2, murine 8-LOX has also been shown to possess anti-tumorigenic and anti-proliferative roles (Kim et al., 2005; Schweiger et al., 2007).
15-LOX2 has at least 6 splice variants (15-LOX2sv-a to 15-LOX2sv-f), which lack appreciable AA-metabolizing activity (Bhatia et al., 2003; Kilty et al., 1999; Tang et al., 2007a; Tang et al., 2002) but, intriguingly, share many biological functions of 15-LOX2. For instance, 15-LOX2sv-b completely lacks AA-metabolizing activity but, like 15-LOX2, could induce cell-cycle arrest in cultured cells (Tang et al., 2002) and inhibits xenograft tumor development (Bhatia et al., 2003), suggesting that 15-LOX2 may possess both enzyme-dependent and -independent biological functions.
Despite our earlier studies implicating 15-LOX2 as a potential tumor suppressor by functioning as an inducer of cell senescence in vitro (Bhatia et al., 2003; Bhatia et al., 2005; Tang et al., 2007a; Tang et al., 2002), it remains unclear whether 15-LOX2 possesses similar functions in a suitable animal model. Furthermore, little is known about the physiological functions of 15-LOX2 in the prostate. To address these deficiencies, we have established prostate-specific 15-LOX2 transgenic mice using the ARR2PB promoter (Zhang et al., 2000). Herein, we report that transgenic expression of 15-LOX2 in mouse prostate induces distinct gene expression profiles and epithelial cell senescence in vivo and induces, unexpectedly, prostatic hyperplasia.
To generate transgenic mice, we cloned full-length 15-LOX2 (fl) or 15-LOX2sv-b (svb) cDNA (Tang et al., 2002) under the control of ARR2PB promoter and microinjected the transgene-containing Kpn1 fragment (Fig. 1A) into the male pronucleus of FVB/N mice. By PCR genotyping, we identified seven fl and six svb potential founder male mice. F1 mice, generated by crossing the positive transgenic founders that passed on the transgene with non-transgenic females, were utilized to characterize the transgene expression using Western blotting (Fig. 1B, C & F), RT-PCR (not shown), and immunohistochemistry (IHC; Fig. 1D & E; fig. S1-S2).
To avoid potential effects of transgene insertion on the prostate phenotype (Kasper et al., 1998; Majumder et al., 2003; Masumori et al., 2001), three fl lines, i.e., fl2 (highest expresser), fl26 (high expresser), and fl15 (low expresser) (Fig. 1B; fig. S1), and three svb lines, i.e., svb9 (high expresser), svb10 (low expresser), and svb16 (lowest expresser) (Fig. 1B; fig. S2) were expanded. All transgenic animals were fertile and overall similar to wild-type (wt) animals in external appearances. The only noticeable change in transgenic animals (compared to age-matched controls) was the increased bladder size and age-associated bladder obstruction (not shown). Western blotting (Fig. 1B, C & F) and IHC on either whole-mount prostate (Fig. 1D-E) or microdissected lobes (fig. S1-S2) revealed that the transgene was expressed, in descending orders, in ventral prostate (VP), lateral prostate (LP), and dorsal prostate (DP) with the anterior prostate (AP) being mostly negative. Genitourinary organs and several other organs examined were negative for transgene expression (Fig. 1C). Overall, the expression patterns of the transgenes, 15-LOX2 or 15-LOX2sv-b, were very similar to those of other transgenes driven by various probasin promoters (i.e., −426/+28 rPB, LPB, and ARR2PB) in several strains of mice (Kasper et al., 1998; Majumder et al., 2003; Masumori et al., 2001). It should be noted that while fl26 animals showed strong and homogeneous 15-LOX2 expression in IHC (Fig. 1Dd & Ed) and Western blot (Fig. 1B), the svb9 prostates frequently exhibited lower and heterogeneous 15-LOX2sv-b staining (Fig. 1B, Fig. 1Df & Ef). This ‘difference’ in transgene expression levels is most likely related to the fact that the polyclonal anti-15-LOX2 antibody used preferentially recognizes 15-LOX2 (i.e., full length) and does not recognize its splice variants very well under harsh denaturing conditions (such as Western blotting and paraffin-embedded IHC) although it does recognize equally well the undenatured proteins of 15-LOX2 splice variants in immunofluorescence staining (Bhatia et al., 2003; Bhatia et al., 2005; see Fig. 6F, below).
15-LOX2 expression levels in the fl transgenic lines correlated well with the 15(S)-HETE-producing activities (Fig. 1G; tables S1 & S2). However, the svb9 and wt prostate lobes showed similar levels of 15(S)-HETE (Fig. 1G; tables S1 & S2), thus corroborating that 15-LOX2sv-b lacks enzymatic activity (Bhatia et al., 2003). No significant differences in 12(S)-HETE or PGE2 levels were observed between transgenic and wt prostates (table S2; data not shown). Importantly, 8(S)-HETE and 9(S)-HODE, the main AA and LA metabolites of murine 8-LOX, respectively, were undetectable in wt as well as transgenic prostates (not shown), consistent with earlier reports that 8-LOX, although inducible by phorbol esters in the mouse epidermis, was not expressed in mouse prostate (Jisaka et al., 1997; Kim et al., 2005; Shappell et al., 2003). Fully consistent with activity measurement, the polyclonal anti-15-LOX2 antibody we employed, which recognizes 15-LOX2 and its splice variants (Tang et al., 2002; Bhatia et al., 2003) as well as murine 8-LOX (Kim et al., 2005), never detected 8-LOX in wt mouse prostates (e.g., Fig. 1B, D, & E). Altogether, these results suggest that we have successfully established mouse prostate-specific expression of human 15-LOX2 or 15-LOX2sv-b.
For all subsequent studies, the fl26 and svb9 transgenic lines were generally used, which expressed similar levels of protein (e.g., see Fig. 6F, below).
The human prostate is an organ that continues to grow with age and 15-LOX2 expression in the human prostate shows an age-related increase (Bhatia et al., 2005). To determine whether 15-LOX2 expression affected the overall prostate development, we microdissected the VP (highest transgene expression), and, for comparison, the AP (no transgene expression) from wild type (n = 91), fl26 (n = 68), and svb9 (n = 74) animals at 2 to 30 months, plotted the log wet weights (in mg) of the prostate lobes as a function of age, and performed linear regression analysis. Much to our surprise, transgene expression appeared to have accelerated the VP ‘growth’ such that at any given age, the transgenic VPs appeared heavier (Fig. 2A) and larger (Fig. 2B) than wt VPs. This was particularly evident with the svb9 VPs (P < 0.0005). On the contrary, APs harvested from the same cohort of animals did not show any significant difference (not shown). When branching morphogenesis of microdissected VPs from 25-30 month-old animals was carried out, the VPs of fl26 and svb9 in particular, showed more complex branching patterns (Fig. 2C), significantly longer branches (Fig. 2D), and more branching points and branch tips (not shown) than the age-matched wt VPs. Similar patterns of differences were also observed in comparisons of younger (i.e., ~6 months) animals (not shown).
To determine the potential cellular mechanisms underlying the transgene-induced VP enlargement, we conducted thorough IHC analysis in both microdissected (Fig. 3) and whole-mount (fig. S3) VP lobes. Surprisingly (considering potential tumor-suppressive functions of 15-LOX2), we observed widespread hyperplasia that correlated with the transgene expression levels (Fig. 3B - C). The svb9 VPs also exhibited hyperplasia (Fig. 3D). Hyperplasia was observed in the VPs of animals as young as 6-10 weeks (fig. S3A). The VPs in older (e.g., 15-month) transgenic animals showed extensive hyperplasia involving >50% of the acini (fig. S3B). Hyperplastic areas showed crowded cells, stratified nuclei, and formation of intraluminal tufts, though true cribriform structures were rarely seen (Fig. 3B-D; fig. S3). Hyperplastic epithelial cells were tall with abundant cytoplasm and many contained prominent secretory material. In some areas of hyperplasia, cells demonstrated nuclear atypia, with nuclear enlargement and prominent nucleoli. Based on these findings, two pathologists (D.K and D.G.T) independently classified the primary lesions in the transgenic VPs as atypical epithelial hyperplasia with lack of evidence of PIN lesions defined as by the Bar Harbor Classification System (Shappell et al., 2004). The transgenic LPs, as expected, manifested less dramatic, though still obvious hyperplastic changes compared to the transgenic VPs (not shown).
Consistent with the hyperplastic phenotypes, we observed significantly increased numbers of Ki-67+ acini/ducts in the 2.5-month transgenic VPs (Fig. 3E), which also had increased numbers of Ki-67+ cells per acinus or duct, especially in the svb9 VP (wt, 1.81±0.014; fl26, 2.3±0.5; svb9, 4.45±0.2). At 15 months, the transgenic VPs still had higher Ki-67+ acini/ducts compared to the age-matched wt animals (Fig. 3E). In contrast to increased Ki-67+ proliferative cells, the transgenic VPs did not show significant changes in apoptosis assessed by caspase-3 staining (not shown).
Prostatic hyperplasia induced by both 15-LOX2 and 15-LOX2svb9 was characterized by significantly increased numbers of luminal cells that stained positive for androgen receptor (AR; fig. S3) and cytokeratin 8 (CK8) (fig. S4). These changes phenotypically resemble the hyperplastic, PIN, and neoplastic lesions in the human prostate wherein the majority of cells are luminal (Abate-Shen and Shen, 2000). IHC staining for CD45 (pan-leukocyte marker) and α-smooth muscle actin did not reveal significant differences between the transgenic vs. wt VPs and between the fl26 vs. svb9 VPs (not shown).
Distinctly, however, the hyperplastic lesions (glands) in the fl26 VPs also showed apparent ‘basal-cell hyperplasia’, characterized by increased numbers of cytokeratin 5 (CK5) and p63 (Signoretti et al., 2000) positive cells, which were observed in young (2.5-month; Fig. 4A) and intensified in older (15-month; Fig. 4B) animals. Western blotting analysis of both 2.5 and 15-month older mice also revealed increased CK5 and p63 protein levels in fl26 VPs compared to age-matched svb9 and wt animals (Fig. 4C). In comparison to fl26 VPs, the svb9 VPs exhibited much less prominent ‘basal-cell hyperplasia’ phenotype (Fig. 4A-C) although the young svb9 VPs did demonstrate slightly increased CK5 protein levels (Fig. 4C).
Despite extensive epithelial hyperplasia in transgenic VPs, no progression to PIN and carcinoma was noticed in >500 animals analyzed with the longest survived animals being ~30-month old. Also, the fl26 prostate lobes generally displayed more severe hyperplasia compared to svb9 VPs but the svb9 VPs showed more prominent organ ‘hypertrophy’ (Fig. 2). These two observations suggest that certain cell-intrinsic mechanism(s) activated by transgene expression, especially in fl26 VPs, might have led to the observed results. One such mechanism could be induction of cell senescence (Bhatia et al., 2005; Tang et al., 2007a). We stained the whole-mount cryosections of young (2.5 – 3 month) and old (15 month) wt and transgenic VPs for senescence-associated β-galactosidase (SA-βgal). As shown in Fig. 5A, the 2.5 month-old fl26 VPs showed stronger SA-βgal staining compared to both wt and svb9 VPs. A strong correlation between transgene expression and SA-βgal staining was observed in the epithelial glands (Fig. 5B). At 15 months, wt VPs, as expected, showed some SA-βgal staining whereas both fl26 and svb9 VPs showed comparable SA-βgal staining, which was overall stronger than that in wt VPs (fig. S5A).
In prostate-specific AKT transgenic mouse (MPAKT) model (Majumder et al., 2008; Majumder et al., 2003), progression of PIN to PCa was blocked by senescence induction associated with upregulation of p27kip1 (p27), a cyclin-dependent kinase inhibitor involved in cell-cycle arrest and senescence, and HP1γ, a heterochromatin-associated protein concentrated in senescent cells. We observed that the p27 (Fig. 5C) and HP1γ (Fig. 5D) expression patterns resembled that of SA-βgal, i.e., both proteins were significantly upregulated in 2.5-month fl26 VPs compared to the wt and svb9 VPs. Semi-quantification of p27 levels by the Allred method (Allred et al., 1998) in whole-mount VPs showed significant increase in p27 nuclear staining in the 2.5-month fl26 VPs (Fig. 5E), as further confirmed by Western blotting (Fig. 5F). Both p27 and HP1γ protein levels in 15 month-old transgenic VPs only showed slight increases over those in wt VPs (fig. S5B-E), perhaps due to the increased ‘background’ levels of p27 and HP1γ in the old wt VPs, similar to SA-βgal staining (fig. S5A).
The above observations suggest that 15-LOX2 induces an early and persistent whereas 15-LOX2sv-b seems to induce a late senescence response in the mouse prostate that involves upregulation of p27 and HP1γ. Subsequently, we carried out a pilot correlation study in human PCa (n = 8) serial sections stained for 15-LOX2, p27 and HP1γ. The results revealed that all three molecules were co-expressed in benign prostatic glands with a good correlation, i.e., those glands that showed strong 15-LOX2 staining also showed distinct nuclear localization of p27 and HP1γ (fig. S6A and C). In contrast, PCa cells generally showed weak or no 15-LOX2 staining with reduced and predominantly cytoplasmic labeling of p27 and reduced HP1γ (fig. S6B and D).
We carried out microarray analysis to compare global gene expression profiles in young (y; 2.5-3.0 month) wt, fl26, and svb9 VPs and old (o; 14-15 month) wt VPs using Agilent’s mouse whole genome oligo arrays. We included the old wt VPs because 15-LOX2 expression correlates with age in the human prostate (Bhatia et al., 2005). When a 1.5 fold-change (FC) cutoff was applied, fl26y(vs)wty comparison revealed 587 upregulated and 105 downregulated genes in the young fl26 VPs, of which 252 upregulated and 47 downregulated genes, respectively, were found to be statistically significant (P<0.05) (Fig. 6A-B; tables S3-S4). In contrast, svb9y(vs)wty comparison only showed 51 upregulated and 28 downregulated genes in the svb9y VPs, of which very few genes showed a P value less than 0.05 (Fig. 6A-B; tables S5-S6). On the other hand, 16 genes were commonly upregulated and 19 genes were commonly downregulated in fl26y and svb9y VPs (Fig. 6A-B; table S7). Interestingly, we observed a significant number of genes commonly upregulated or downregulated between the wto(vs)wty and fl26y(vs)wty comparisons as well as between the wto(vs)wty and svb9y(vs)wty comparisons (Fig. 6A-B; table S7).
Among the genes upregulated in the fl26y prostates were p63 and CK5 (Table 1), whose protein levels were also upregulated as revealed in our earlier IHC and Western blotting analyses (Fig. 4A-C). The upregulation of several other randomly picked molecules including Rb1cc1, clusterin, calcitonin and Nupr1 that were upregulated in fl26y VPs in microarray (Table 1; table S3) was also confirmed by quantitative RT-PCR (qPCR) and/or IHC analyses (Fig. 6C-F). Importantly, qPCR analysis of RNA prepared from epithelial glands isolated by laser capture microdissection (LCM) confirmed the epithelial-specific differences in gene expression levels between 6-month-old wt and transgenic VPs (Fig. 6D). Interestingly, two of the four molecules examined, i.e., clusterin and Nupr1, also showed some upregulation in svb9y VPs (Fig. 6C, D & F), in contrast to microarray data (table S5).
Gene ontology (GO) analysis of the upregulated genes revealed interesting differential gene expression patterns (Table 1; table S3) that could help explain the prostate phenotypes in the transgenic animals. First, both CK5 and p63 were upregulated in fl26y (Table 1), corroborating the ‘basal cell hyperplasia’ phenotype in the fl26 VPs (Fig. 4). In addition, at least 5 other well-established (prostate) stem/progenitor cell markers (Lawson and Witte, 2007; Tang et al., 2007b) including Sca-1 (Lawson and Witte, 2007), Trop2 (Goldstein et al., 2008), Klf4 (Okita et al., 2008), Psca (Tran et al., 2002), and Nkx3.1 (Wang et al., 2009) were also upregulated preferentially in fl26y VPs compared to svb9y. Second, the fl26y VPs also upregulated several cell-cycle proteins such as cyclin D2 and Pcna (proliferating cell nuclear antigen) as well as positive regulators of proliferation such as K-ras, MAPK and PI3K pathway molecules (Table 1). Very few of these molecules were upregulated in the svb9y VPs, suggesting that 15-LOX2 and 15-LOX2sv-b promotes cell proliferation in mouse prostate (Fig. 3E) via different molecular mechanisms. Third, the fl26y(vs)wty comparison revealed prominent upregulation of angiogenin molecules (i.e., angiogenin 1-4) (Table 1), which were also upregulated in some other prostate-restricted transgenic models (Dillner et al., 2003; Kindblom et al., 2003; Majumder et al., 2003) and have been recently implicated in PCa development and progression through regulating angiogenesis and proliferation (Ibaragi et al., 2009; Katona et al., 2005; Yoshioka et al., 2006). Interestingly, all 4 angiogenin molecules were significantly upregulated in the wto(vs)wty but none was upregulated in the svb9y(vs)wty VPs (table S5 & table S7). Finally, in addition to these distinct gene expression profiles, many genes were commonly up- or downregulated in fl26y(vs)wty, svb9y(vs)wty, and wto(vs)wty comparisons (table S7; data not shown).
The current project was undertaken to probe the in vivo biological activities of the functional tumor suppressor 15-LOX2, whose expression is reduced or lost in PCa. Through establishment and characterization of prostate-specific 15-LOX2 transgenic mice, we report several surprising and interesting findings (Fig. 7). Expression of 15-LOX2 in mouse prostate, unexpectedly, leads to prostatic hyperplasia associated with increased cell proliferation and increased numbers of both luminal and basal cells. Expression of 15-LOX2sv-b, a splice variant that lacks AA-metabolizing activity, results in a moderate epithelial hyperplasia but apparent prostate enlargement associated with increased cell proliferation and luminal cells only (Fig. 7). Prostatic hyperplasia induced by both 15-LOX2 and 15-LOX2sv-b does not progress to PIN or carcinoma, likely due to the induction of cell senescence.
15-LOX2 reduces proliferation, induces senescence, and inhibits xenograft tumor development when ectopically expressed in PCa cells. Therefore, it came as a surprise to us that transgenic expression of 15-LOX2, and enzymatically inactive 15-LOX2sv-b in particular, resulted in enlargement of mouse prostate, which, histologically, is characterized by epithelial hyperplasia. The fl VPs consistently display more severe hyperplastic lesions than age-matched svb VPs. One possible explanation is that, compared to svb VPs, the fl VPs demonstrate significantly increased numbers of not only luminal cells but also basal cells that stain positive for CK5 and p63 (Fig. 7). This basal-cell hyperplasia is associated with gene expression changes in CK5, p63, Nkx3.1, and Sca-1 as well as a novel prostate stem cell marker Trop2 (Goldstein et al., 2008), suggesting that 15-LOX2 expression results in increases in both basal cells and perhaps p63+/Sca-1+/Trop2+ stem/progenitor cells in the basal layer, the latter of which in turn could give rise to more luminal cells. Consequently, increased cellularity in both basal and luminal compartments contribute to the more prominent hyperplasia phenotype observed in the fl VPs (Fig. 7).
Why is basal-cell hyperplasia only observed in the fl transgenic VPs and how could we reconcile the seeming contradiction of tumor-suppressive effects of 15-LOX2/15(S)-HETE in vitro (Tang et al., 2007a) versus increased proliferation and hyperplasia in fl VPs? One explanation could be related to the unique biochemical properties of 15-LOX2, which metabolizes predominantly AA to generate 15(S)-HETE but can also metabolize LA to produce some 13(S)-HODE (Kilty et al., 1999). Indeed, in the fl transgenic VPs, we have observed significantly higher levels of not only 15(S)-HETE (table S1) but also 13(S)-HODE (table S2), suggesting that 15-LOX2 in mouse prostate is producing a significant amount of 13(S)-HODE from LA, available from the chow. This increase in 13(S)-HODE could potentially explain the severe hyperplasia in the fl VPs as 13(S)-HODE, the principal metabolite of 15-LOX1, possesses protumorigenic functions in PCa cells (Spindler et al., 1997) and transgenic expression of 15-LOX1 in mouse prostate results in hyperplasia and PIN via over-production of 13(S)-HODE (Kelavkar et al., 2006). Since 15-LOX2 in our transgenic model is directed to the luminal cell compartment by ARR2PB promoter, presumably, the luminal cell-derived 13(S)-HODE acts on the basal (stem/progenitor) cells to promote their proliferation (Fig. 7). The svb9 VPs, on the other hand, do not show increased levels of 13(S)-HODE (table S2) and thus lack the basal-cell hyperplasia phenotype. How 15-LOX2sv-b induces prostatic hyperplasia remains presently unclear.
Genome-wide cDNA microarray analysis has revealed nearly 600 up-regulated and 100 downregulated genes in the fl26 VPs but only ~50 upregulated and 28 downregulated genes in svb9 VPs, compared to the age-matched young wt VPs (Fig. 7). The significantly more upregulated genes in the fl26 VPs are almost certainly related to the ability of 15-LOX2 to produce 15(S)-HETE and 13(S)-HODE (Fig. 7). On the other hand, it is remarkable that 16 of the 51 genes upregulated and 19 of the 28 genes downregulated in the young svb9 VPs are shared with the fl26 VPs, suggesting strongly that as we proposed earlier (Bhatia et al., 2003), 15-LOX2 possesses AA/LA metabolism-independent biological functions (Fig. 7).
Among the genes upregulated in the fl26 VPs, many are positive cell-cycle molecules (e.g., cyclin D2, Pcna) or positive regulators of cell proliferation (e.g., K-ras, Mapk, Pik3) and, strikingly, are also upregulated in two other transgenic prostate models, i.e., MPAKT (Majumder et al., 2003) and PB-PRL (Dillner et al., 2003; Kindblom et al., 2003), both of which also manifest conspicuous hyperplastic lesions (table S8). For example, MPAKT VPs, mainly characterized by PIN lesions (Majumder et al., 2003), and fl26 VPs share ~15% identical (e.g., Ang 2, Ang, 3, Trop2, Psca, Fgfbp1, Saa1 and Saa2) and ~40% similar upregulated genes (table S8). Likewise, PB-PRL VPs, which display stromal hyperplasia with mild epithelial hyperplasia (Dillner et al., 2003; Kindblom et al., 2003), share ~13% identical and ~30% similar upregulated genes with the fl26 VPs (table S8). Among the 17 identical genes are Ang 4, clusterin, and several ECM proteins including vimentin, col3a1, and laminin (table S8). These similarities suggest that transgenic expression of 15-LOX2 may cause not only epithelial hyperplasia but also some stromal alterations. By comparison, the svb9 VPs show many fewer changes in gene expression and the majority of the up- and downregulated genes in fl26 VPs are not observed in svb9 VPs (Fig. 7). On the other hand, increased levels of Clu and Nupr1 in svb9y VPs observed by qPCR suggest that inter-animal variability commonly associated with animal studies might have masked differential expression of at least some genes in the svb9 animals when analyzed by microarray.
How do we explain that although fl26 VPs exhibit more severe hyperplasia than svb9 VPs, the latter appear bigger and display more conspicuous organ ‘hypertrophy’? A possible explanation could be that 15-LOX2, both in vitro (Bhatia et al., 2005) and in vivo (this study), seems to be a stronger inducer of cell senescence than 15-LOX2sv-b. Hence, 2-3 month fl26 VPs already show prevalent senescence, which persists throughout adulthood; in contrast, increased senescence is observed only in old svb9 VPs. Consequently, despite that 15-LOX2 induces prominent cell proliferation and hyperplasia, early induction of senescence presumably cancels out the proliferation-induced increases in both luminal and basal cells. As a result, 15-LOX2 only causes mild prostate enlargement compared to 15-LOX2 svb9 (Fig. 7).
How 15-LOX2 elicits cell senescence at the molecular level is presently unclear. Since 15(S)-HETE can act as a ligand for PPARγ to induce gene transcription (Chen et al., 2003; Subbarayan et al., 2006), we are tempted to speculate that 15-LOX2, partially localized in the nucleus (Bhatia et al., 2003) and perhaps via intranuclear production of 15(S)-HETE, preferentially activates a set of genes such as Rb1cc1 (Table.1; Fig. 6 C-E) in fl26 VPs. Rb1cc1 can in turn induce Rb1 (Chano et al., 2002; Ikebuchi et al., 2009) and p21 by physically interacting with p53 (Melkoumian et al., 2005), all of which are important players of senescence. Microarray analysis also identifies a subset of genes commonly up- and down-regulated in fl26 and svb9 VPs (Fig. 7), some of which might be involved in 15-LOX2-induced but largely responsible for 15-LOX2sv-b-caused cell senescence.
Since cell senescence is a strong suppressor of progression from hyperplastic lesions to overt tumor development (Braig et al., 2005; Chen et al., 2005; Majumder et al., 2008), we hypothesize that 15-LOX2-elicited cell senescence functions as a barrier to hyperplasia-to-tumor progression in our transgenic animals. This hypothesis is strongly buttressed by the fact that the 15(S)-HETE-elicited senescence seems to predominate over the 13(S)-HODE-promoted hyperplasia in ultimately preventing progression of hyperplasia to PIN/tumor (Fig. 7). We are currently testing this hypothesis by crossing fl26 mice to Hi-Myc mice (Ellwood-Yen et al., 2003), which develop invasive adenocarcinoma in the prostate.
The transgene constructs (see Fig. 1A) were made by placing 15-LOX2 and 15LOX2sv-b cDNA (Tang et al., 2002) under the control of ARR2PB promoter (Zhang et al., 2000), intervened by the rabbit β-globin second intron sequence that increases transgene expression and followed by β-globin-SV40 hybrid polyA sequences (Chen et al., 2009). The ~4.2 kb Kpn I fragments containing the transgenes were gel-purified and microinjected into the male pronucleus of FVB/N mice. Male founder mice were identified by PCR genotyping of tail-clip DNA using primers C (sense, 5′- ACTACCTCCCAAAGAACTTCCCC-3′) and D (antisense, 5′-TTCAATGCCGATGCCTGTG-3′), or using primers F2 (sense, 5′-GGTCATCATCCTGCCTTTC-3′; in the β-globin intron) and R1 (antisense, 5′-CGATGCTGACAGACACTTTG-3′; in the transgene cDNA). PCR of β-actin was used as control. All the procedures involving the usage of animals were approved by Institutional Animal Care and Use Committee (IACUC).
Detailed procedure was described elsewhere (Sugimura et al., 1986). Briefly, the prostate was removed along with the urogenital tract. The organs were placed immediately in ice cold Hank’s Buffered Salt Solution (HBSS) and microdissected under a dissection microscope. One of the two VP lobes was then incubated in 1% collagenase in HBSS on Maximov depression slide for 10 min and branches were separated using fine forceps. From the branched VP, branch tips were counted and branch lengths were measured.
From a separate group of wt and transgenic mice, the wet weights of both lobes of the VP and AP (as control) were collected at different ages from 2 to 30 months. Weights (in mg) were plotted as a function of animal age and regression analysis was carried out to test the significance of differences in the weights of prostatic lobes between transgenic and wt mice.
Basic procedures for microarray experiments were recently described (Bhatia et al., 2008). In brief, VP lobes were removed and submerged in 50 μl of RNALater at 4°C for 1-2 days, RNALater was then removed and the prostate lobes were frozen at −80°C until processed. VP lobes from 6 mice of the same genotype were combined to reduce the inter-animal variability. The combined frozen VP lobes were crushed in a BioPulverizer (Biospec Products, Inc). RNA was isolated using RNA mini prep kit for VPs of 2.5 – 3 months old (young) animals (17-29 mg) and midi prep kit for VPs of 14-16 months (old) animals (38-64 mg) according to the manufacturer’s instructions utilizing syringe homogenization. RNA was quantified using the Nanodrop ND-1000 and RNA integrity analyzed by Agilent Bioanalyzer. Microarray experiments were carried out using the 44K whole mouse genome oligo arrays from Agilent (G4122A). RNA from young (y) and old (o) wt and young transgenic (fl26 & svb9) VPs was hybridized onto dual channel arrays in wt old vs. wt young, fl26 young vs. wt young, and svb young vs. wt young combinations in biological replicates.
The array data were subjected to LOWESS normalization and the normalized data were used for calculating fold changes (FC) of up- and downregulated genes in each individual comparison. A paired t-test was carried out for each comparison to obtain P values. Venn Diagram analysis was carried out by using Venn Diagram analysis module from ArrayTrack microarray analysis suite developed by FDA’s NCTR (Fang et al., 2009). GO analysis was carried out by using WebGestalt (WEB-based GEne SeT AnaLysis Toolkit) developed and maintained by Bioinformatics Resource Center at Vanderbilt. All microarray data have been deposited in NCBI GEO database (accession # GSE158;http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=xvmphckuguyoqrm&acc=GSE15827).
We gratefully thank Dr. R. Matusik (Vanderbilt University) for providing the ARR2PB promoter, D. Holowell for transgenic related studies, Dr. H. Thames and K. Lin for assistance in statistics, the Histology Core for help in IHC, Animal Facility Core for animal related experiments, Molecular Biology Core, especially J. Repass for assistance in qPCR analysis, C. Perez for assistance in LCM, S. Gaddis, L. Shen and S. Tsavachidis for assistance in microarray analysis, Drs. S. Fischer and C. Jeter for critically reading the manuscript, and other members of the Tang lab for support and helpful discussions. This work was supported in part by grants from NIH (R01-AG023374, R01-ES015888, and R21-ES015893-01A1), American Cancer Society (RSG MGO-105961), Department of Defense (W81XWH-07-1-0616 and W81XWH-08-1-0472), and Elsa Pardee Foundation (D.G.T) and by two Center Grants (CCSG-5 P30 CA016672 and ES07784).